arrow
S

Stephan Bartels

hannover medical school
H指数:20
被引数:1,030

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Genomic profiling identifies actionable DNA-repair defects in a new cervical cancer model

基因组分析鉴定出一种新型宫颈癌模型中可操作性的DNA修复缺陷

2026-07-290
OAAI
Germline variants in ATM, BRCA2, other cancer predisposition and novel candidate genes are implicated in glioma risk in adult glioma patients with a familial or personal history of tumors

ATM,BRCA2,其他癌症易感性和新候选基因的种系变异与具有家族或个人肿瘤史的成年神经胶质瘤患者的神经胶质瘤风险有关。

2026-01-170
OAAI
Integrative analysis of RNA expression signatures and recurrent genomic alterations before treatment: link to menopausal status, short-term endocrine therapy response and disease-free survival in luminal breast cancer

RNA表达特征与复发基因组改变的整合分析:治疗前与绝经状态、短期内分泌治疗反应及无病生存期的关联性研究(在腔面乳腺癌中)

2025-11-210
OAAI
Clinical practice and implications of biomarker testing in biliary tract cancer: an observational study☆

胆道癌中生物标志物检测的临床实践与意义:一项观察性研究☆

2025-11-040
OAAI
A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders

一个预测性内分泌抵抗指数能够准确地对腔面型乳腺癌治疗反应者和非反应者进行分层。

2025-10-012
OA
Clinicopathological Characteristics of a Distinct Tumor Phenotype: Invasive Lobular Carcinoma With Tubular Elements in the West German Study Group ADAPTcycle Trial
2025-06-010
OA
Circulating tumor DNA (ctDNA) for prediction of pathologic complete response (pCR) after 12 weeks of pembrolizumab plus trastuzumab plus pertuzumab in HER2-enriched early breast cancer: WSG-Keyriched-1 trial
2024-05-020
PRE
Microenvironment-induced restoration of cohesive growth associated with focal activation of P-cadherin expression in lobular breast carcinoma metastatic to the colon
2024-01-183
OAAI
Combined biomarker analysis for prediction of pathological complete response (pCR) after 12 weeks of pembrolizumab plus trastuzumab plus pertuzumab in HER2-enriched early breast cancer: Keyriched-1 trial
2023-03-010
PRE
First proficiency testing for NGS-based and combined NGS- and FISH-based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma
2023-01-124
OAAI
KEYRICHED-1-A prospective, multicenter, open label, neoadjuvant phase II single arm study with pembrolizumab in combination with dual anti-HER2 blockade with trastuzumab and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype
2022-02-151
PRE